The latest news from ANGLE
February 13, 2017
ANGLE plc (AIM: AGL OTCQX: ANPCY), the specialist medtech company, is pleased to announce that it has been formally selected for CANCER-ID, the European consortium to validate blood-based biomarkers for cancer.
CANCER-ID is a European consortium funded by the Innovative Medicines Initiative (IMI), with a total budget exceeding €14 million, bringing together 38 partners from 13 countries, and aimed at the establishment of standard protocols for and clinical validation of blood-based biomarkers to enable liquid biopsies to become routine clinical practice.
University Medical Center Hamburg-Eppendorf, University of Twente, Bayer AG and Menarini Silicon Biosystems coordinate the consortium, bringing together experts from academic and clinical research to the life sciences industry to provide a unique setting to establish the clinical utility of liquid biopsies.
January 26, 2017
ANGLE plc (AIM:AGL OTCQX:ANPCY), the specialist medtech company, is delighted to announce the outcome from the planned interim evaluations of two separate 200 patient ovarian cancer studies, in Europe and the United States.
The early evaluation of data from both the studies suggest that an assay using the Parsortix system could accurately differentiate between women with a malignant pelvic mass and those with benign tumours, with an additional benefit of providing valuable gene expression information which could help further refine treatment decisions. Such data, if confirmed over the remaining samples, would represent an advantage over currently available clinical risk assessment tools.
ANGLE WELCOMES NEW RESEARCH FROM BARTS SUPPORTING POTENTIAL USE OF PARSORTIX TO DETECT AND MONITOR PROSTATE CANCER
November 4, 2016
ANGLE plc welcomes new research presented during the National Cancer Research Institute (NCRI) annual conference, 6-9 November 2016, which supports the potential use of the Company’s Parsortix cell separation technology. This research details the use of Parsortix as part of a simple blood test, to diagnose and monitor patients with prostate cancer.
September 30, 2016
ANGLE plc today announces that University Medical Centre Hamburg-Eppendorf (UKE) has published new research detailing the use of ANGLE’s ParsortixTM system in the prestigious peer-reviewed journal Clinical Chemistry. The paper is entitled “Accession of Tumor Heterogeneity by Multiplex Transcriptome Profiling of Single Circulating Tumor Cells” 1.
July 27, 2016
ANGLE plc is pleased to announce that it has initiated an ovarian cancer study in the United States, in addition to its recently opened European ovarian cancer study. The US study is being led by Dr Richard Moore at the University of Rochester Medical Center Wilmot Cancer Institute (New York State).
July 19, 2016
ANGLE plc is pleased to announce that its European ovarian cancer study has been formally initiated and has recruited its first patient.
July 15, 2016
ANGLE plc (AIM:AGL OTCQX:ANPCY), the specialist medtech company, is pleased to announce that significant profile was achieved for ANGLE’s Parsortix system at EACR 2016 (the European Association for Cancer Research Biennial Meeting) held in Manchester 9 to 12 July 2016.
CANCER RESEARCH UK MANCHESTER INSTITUTE ADOPTS PARSORTIX FOR ROUTINE USE WITHIN CLINICAL TRIALS PORTFOLIO
May 25, 2016
ANGLE plc (AIM:AGL OTCQX:ANPCY), the specialist medtech company, is delighted to announce that it has signed a contract with The University of Manchester, acting in this instance, through the Cancer Research UK Manchester Institute which will allow incorporation of ANGLE’s Parsortix system in the Clinical and Experimental Pharmacology group for routine use in clinical trials and for research purposes.
USC PATIENT DATA DEMONSTRATES POTENTIAL OF PARSORTIX FOR METASTATIC BREAST CANCER LIQUID BIOPSY CLINICAL APPLICATION
April 18, 2016
ANGLE plc (AIM:AGL OTCQX:ANPCY), the specialist medtech company, is delighted to announce that the results of the University of Southern California (USC) Norris Comprehensive Cancer Center’s ongoing work with ANGLE’s Parsortix system have demonstrated the potential for the use of Parsortix as a liquid biopsy for metastatic breast cancer.
BARTS PATIENT DATA DEMONSTRATES POTENTIAL OF PARSORTIX FOR PROSTATE CANCER DETECTION CLINICAL APPLICATION
March 21, 2016
Potential for a simple blood test to not only detect prostate cancer but also to assess the aggressiveness of the disease allowing risk stratification to active surveillance or intervention